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Background: For clinicians, it is important to rely on accurate laboratory results for patient care and optimal use of
health care resources. We sought to explore our observations that urine protein:creatinine ratios (PrCr) ≥30 mg/mmol
are seen not infrequently associated with normal pregnancy outcome.
Methods: Urine samples were collected prospectively from 160 pregnant women attending high-risk maternity clinics
at a tertiary care facility. Urinary protein was measured using a pyrocatechol violet assay and urinary creatinine by an
enzymatic method on Vitros analysers. Maternal/perinatal outcomes were abstracted from hospital records.
Results: 91/233 (39.1%) samples had a PrCr ≥30 mg/mmol, especially when urinary creatinine concentration was
<3 mM (94.1%) vs. ≥3 mM (16.4%) (p < 0.001). When using the last sample before delivery, 47/160 (29.4%) had a PrCr
≥30 mg/mmol in diluted urine vs. only 17/160 (15.4%) in more concentrated urine (p < 0.001); PrCr positive results
were also more frequent among the 32 (20.0%) women with known normal pregnancy outcome (90.9% vs. 0)
(p < 0.001). Using the same analyser, 0.12 g/L urinary protein was ‘detected’ in deionised water. Re-analysis of data from
two cohorts revealed substantially less inflation of PrCr in dilute urine using a pyrogallol red assay.
Conclusions: Random urinary PrCr was overestimated in dilute urine when tested using a common pyrocatechol
violet dye-based method. This effect was reduced in cohorts when pyrogallol red assays were used. False positive
results can impact on diagnosis and patient care. This highlights the need for both clinical and laboratory quality
improvement projects and standardization of laboratory protein measurement.
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Accurate proteinuria results are key to the management of
adults and children with chronic kidney disease [1], as well
as women with a hypertensive disorder of pregnancy [2].
The most commonly used methods of detection of pro-
teinuria in pregnancy are: urinary dipstick by visual or
automated testing, random protein to creatinine ratio
(PrCr), or 24-hour urine collections. The random PrCr
has been recommended as a confirmatory test for pre-
eclampsia, defined as a random PrCr ≥30 mg/mmol [2]* Correspondence: LMagee@cw.bc.ca
4Department of Specialized Women’s Health, British Columbia Women’s
Hospital and Health Centre, 4500 Oak Street, Room 1U59, Vancouver, BC V6H
3N1, Canada
5Department of Medicine, University of British Columbia, Vancouver, Canada
Full list of author information is available at the end of the article
© 2013 De Silva et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(www.nice.org.uk/cg107). Since 2009 at our institution,
we have used this test more and more for outpatients
and inpatients as an easy and timely alternative to
24-hour urine collection for proteinuria determination.
However, it has been our clinical impression that there
are a number of women who have urinary PrCr values
above diagnostic threshold, yet, have normal pregnancy
outcomes. We are also aware of possible false positive
results outside pregnancy in a community screening
study [3].
We sought to investigate our impression that an
elevated PrCr result may be associated with normal
pregnancy outcome, and if so, to consider potential ex-
planations related to physiology and analytical method.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This pragmatic cohort study took place at BC Women’s
Hospital & Health Centre in Vancouver, BC from January
27 to March 31, 2011. Consecutive high-risk inpatient or
outpatient pregnant women were prospectively evaluated.
All women who presented for hypertension in the assess-
ment room or delivery suite or seen at our (primarily
morning) ambulatory medicine or high-risk obstetric
clinics were included. Women were excluded if they had
ruptured membranes or were in labour. As this was a
quality improvement study for the hospital laboratory,
consent was not required. This study was approved by the
University of British Columbia Clinical Research Ethics
Board (H10-02691).
Random midstream urine samples obtained as part of
normal clinical care were split into two aliquots; women
are not routinely asked to provide first-voided urines, but
rather, they provide the sample when they arrive at the
clinic. The first was used for urinary dipstick testing. The
second aliquot was sent to the hospital laboratory where it
was centrifuged at a speed of 1500 rpm for 5 minutes, and
then tested for urinary PrCr in batches on an automated
analyser (Vitros 5,1 FS or Vitros 5600, Ortho-Clinical
Diagnostics, Rochester, NY) as is standard laboratory pro-
cedure. Testing included urinary creatinine (using an en-
zymatic method) and protein (using a pyrocatechol violet
molybdate dye-binding method), followed by calculation
of the urinary PrCr [4,5]. The manufacturer lists limits of
detection of 0.05 g/L for protein and 0.106 mmol/L for
creatinine. The coefficients of variation of the protein and
creatinine assays are 2.9% at a concentration of 0.3 g/L
and 2.0% at a concentration of 5.3 mM, respectively. In
addition to the routinely collected, visually interpreted
urinary dipstick testing performed in the clinic, clinicians
also received the results of the urine PrCr.
Hospital records were used to abstract maternal and
perinatal outcomes. Maternal outcomes included demo-
graphics, parity, multiple pregnancy, details of the indica-
tion for attendance at the high-risk clinic and other
medical co-morbidities, antenatal complications such as
haemorrhage or preterm labour, and delivery information
including mode of delivery. Perinatal outcomes included
stillbirth, neonatal death, birthweight, and neonatal inten-
sive care unit (NICU) admission.
In our exploratory analysis, we plotted the creatinine
concentration (mM) against the PrCr (mg/mmol) for all
random urine samples submitted (as some women pro-
vided more than one urine sample). Then we focused on
using the last random urine sample submitted before de-
livery. In response to the results, we performed sensitivity
analyses in which we included only urine samples with a
specific gravity (SG) >1.010 and samples from women
with no dipstick hematuria. Samples from women with
normal pregnancy outcome (i.e., no evidence of pre-eclampsia and a term delivery of an appropriately grown
infant) were highlighted in all analyses. We then per-
formed a dilution study on a new random urine sample
with a protein result in the low-mid area of the Vitros
assay analytical range of 0.05 – 2.00 g/L. 1:2, 1:3, 1:4, and
1:5 dilutions of the urine were made using either deionised
water or saline as the diluent and tested for urinary pro-
tein on the analyser. To verify whether our findings were
related to the urinary protein method used, we repeated
our statistical analyses in two separate published cohorts
of women in which proteinuria was determined using a
pyrogallol-based dye-binding urine protein assay [6,7].
The Pearson’s Chi-squared test and Fisher’s exact test
were used to calculate p values where appropriate.
Results
The 160 women in the study cohort provided 233 samples
at one/more antenatal visits, although most women (114
or 71.3%) provided only one sample. Table 1 presents the
baseline characteristics of this study cohort. Most women
had singleton pregnancies, were evaluated as outpatients
in the second trimester, and were not receiving antihyper-
tensive therapy at the time of urine sampling. One third of
women had a hypertensive disorder of pregnancy at sam-
pling, most commonly pre-existing hypertension.
Preliminary analysis for all samples
All 233 random urine samples were assayed for PrCr of
which 91 (39.1%) were ≥30 mg/mmol. 50 (21.5%) sam-
ples had urine protein below the assay detection limit,
and their PrCr values were calculated using the assay
cut-off for protein of 0.05 g/L; all 50 had PrCr <30 mg/
mmol. The relationship between urinary creatinine con-
centration and the random PrCr result is presented for
all samples in Figure 1. Low urinary creatinine concen-
tration (defined as those <3 mM) was associated with
higher urinary PrCr results (≥30 mg/mmol) regardless of
pregnancy outcome.
Detailed analysis for last sample before delivery
The relationship between urinary creatinine concentration
and the random PrCr is presented for the last sample pro-
vided before delivery in Figure 2. 50 (31.3%) samples were
dilute (i.e., with urine creatinine concentration <3 mM)
and 55/159 (34.6%) samples had dipstick specific gravity
(SG) ≤1.010. Low urinary creatinine concentration was still
associated with higher urinary PrCr results (Figure 2A).
The same relationship was seen for samples with urin-
ary dipstick SG >1.010 (Figure 2B), or when samples
with dipstick hematuria and leukocytes were excluded
(Figure available upon request).
In response to the relationship to urine concentration
we found, we looked at the time of day urine samples
were collected. Most women (128/160; 80.0%) provided
Table 1 Baseline characteristics of the 160 women in the study cohort (N (%) or median [interquartile range],
as appropriate)
N = 160 women
Maternal characteristics
Maternal age (yr) 34 [31–37]
Primiparous 75 (46.9%)
Multiple pregnancy 5 (3.1%)
Pregnancy characteristics at the time of urine sampling
Outpatient 131 (81.9%)
N samples collected before 1300 hours 128 (80%)
Gestational age when urine sample taken 24 [20–32]
On antihypertensive therapy 31 (19.4%)
Hypertensive disorder at sampling 61 (38.1%)
Pre-existing hypertension only 25 (15.6%)
Pre-existing hypertension with baseline proteinuria 3 (1.9%)
Gestational hypertension without dipstick proteinuria 19 (11.9%)
Pre-eclampsia (including HELLP syndrome) 14 (8.8%)
Medical co-morbidities other than hypertension
Women with one/more co-morbidity 60 (37.5%)
Women with two or more co-morbidities 21 (13.1%)
Specific co-morbidities (N women)
Diabetes (pre-gestational or gestational) 16 (10%)
Pre-existing kidney disease* 8 (5%)
Other co-morbidities† 47 (29.4%)
Pregnancy outcome after urine sampling (N = 112 women with known pregnancy outcome)
Delivery at BCWH or post-partum follow-up 112 (70%)
Not known or lost to follow-up 48 (30%)
Miscarriage or elective termination 4 (3.6%)
Stillbirth 1 (0.9%)
Placental abruption or other APH 3 (2.8%)
Preterm pre-labour rupture of membranes 4 (3.7%)
Chorioamnionitis 1 (0.9%)
Gestational age at delivery (wk) 38 [37–39]
Delivery at <37 wk 17 (15.7%)
Caesarean section 52 (48.1%)
Small for gestational age infants 19 (17.6%)
Neonatal intensive care unit admission 12 (11.1%)
APH (antepartum haemorrhage), BCWH (British Columbia Women’s Hospital and Health Centre), HELLP (haemolysis, elevated liver enzyme, low platelet) syndrome.
* No women had acute kidney injury. All eight women with chronic kidney disease were outpatients. Their serum creatinines ranged from 48-207 μM with only
one woman having a pre-recruitment serum creatinine >90 μM.
† Other medical co-morbidities included the following (N women): thyroid disorders (15), systemic lupus erythematosus (6) or another connective issue disorder
(4), depression (5), anemia (4), antiphospholipid antibody syndrome (3), polycystic ovarian syndrome (2), multiple sclerosis (2), immune thrombocytopenia (2),
Raynaud’s (2), diabetes insipidus (1), hypercholesterolemia (1), biliary colic (1), deep vein thrombosis (1), polycythemia vera (1), polymyositis (1), scleroderma (1),
pulmonary fibrosis (1), Addison’s disease (1), Crohn’s disease (1), celiac disease (1), histiocytosis (1), hepatitis B (1), hyperaldosteronism (1), asymptomatic
bacteriuria (1), and/or solitary kidney (1).
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patient clinics were run in the morning. The random
urine samples collected in the morning were not more
concentrated in the morning when looking at urinarycreatinine concentration according to time of the col-
lection during the day (Figure 3).
There were no clinical concerns about urinary tract in-
fection but women could have had renal disease. By
Figure 1 Random urinary protein:creatinine ratio (PrCr, mg/mmol) according to urinary creatinine concentration for all random urine
samples (N = 233) (mmol/L). The horizontal dotted line represents a PrCr of 30 mg/mmol, the current cut-off for detection of 0.3 g/d of
proteinuria. The vertical dotted line represents a urinary creatinine concentration of 3 mmol/L. Women with known normal pregnancy outcome
are represented by the darker circles.
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positive for red blood cells (RBC); urine microscopy was
routinely performed for the 29 inpatients only if samples
tested positive (as per standard laboratory practice) and
2/16 (12.5%) samples had >3 RBC per high power field.
53/159 samples (33.3%) tested positive for leukocyte
esterase, which tests for presence of white blood cells.
Of those that had urine microscopy performed, 7/16
(43.8%) samples had >5 WBC per high power field. Only
one (0.6%) tested positive for nitrites. No sample had a
positive urine culture for bacteria.
Table 2 presents the number of samples with PrCr ≥
30 mg/mmol as a percentage of those with low (<3 mM)
or high (≥3 mM) urine creatinine concentration, for the
groups presented in Figures 1 and 2A-B. Also presented
are the relationships between urinary creatinine concen-
trations and PrCr in two other cohorts of women who
had been recruited from our centre for different studies.
24 hr urinary completeness cohort
As our hospital used a manual pyrogallol red dye-based
urine protein assay until 2009, we explored the relation-
ship between urinary creatinine concentrations and (24-
hour) PrCr in a cohort of 198 women who had a 24-hour
urine collection for protein at our hospital between 1997
and 2004 [6]. This cohort consisted of pregnant women
with a hypertensive disorder (including 63.1% with pre-
eclampsia and 23.7% with pre-existing hypertension). The
creatinine assay was similar (Vitros 250/950, OrthoClinical Diagnostics, Rochester, NY.) 161 (81.3%) of
women were inpatients, and 24-hour urine creatinine con-
centration was <3 mM in 17 (10.6%). There was no clear
pattern of increased urine PrCr at low urine creatinine
concentration as shown in Table 2 and presented graphic-
ally in Figure 4.
PIERS cohort
In a dataset of women admitted to hospital with pre-
eclampsia or who developed pre-eclampsia and had not
yet presented with one of the serious outcomes [7], the in-
flation of urinary PrCr (measured on 24-hour urine sam-
ples) at low urinary creatinine concentration was marked
for samples run using the Vitros method (N = 468 sam-
ples), but the effect largely disappeared for those run be-
fore 2009 using the pyrogallol red method (N = 2432
samples) (Table 2). These results are available online
(Additional file 1: Figure S1). For random PrCr results, the
same pattern of inflated PrCr values was seen at low
urinary creatinine concentration with Vitros but to a less
extent with pyrogallol red (Table 2, Additional file 2:
Figure S2).
To investigate the role of the Vitros protein assay on
our results, dilution studies were undertaken on a new
random urine sample using deionised water as the diluent
(as recommended by the manufacturer). There was an
excellent correlation between expected and measured
concentrations of protein (R2 = 0.99927). However, as
shown in Table 3, diluted urine consistently showed
Figure 2 Random urinary protein:creatinine ratio (PrCr, mg/mmol) according to urinary creatinine concentration using the last sample
before delivery (mmol/L). A) Last urine samples provided. B) Excluding urine samples with specific gravity (SG)≤ 1.010. The horizontal dotted
line represents a PrCr of 30 mg/mmol, the current cut-off for detection of 0.3 g/d of proteinuria. The vertical dotted line represents a urinary
creatinine concentration of 3 mmol/L. Women with known normal pregnancy outcome are represented by the darker circles.
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by the ‘recoveries’ (measured protein result as a percent-
age of calculated expected concentration). The problem
was less apparent when the diluent used was saline, which
has a higher ionic strength than water. The analyser gave
protein results when pure deionised water and saline were
tested, at concentrations of 0.12 g/L and 0.06 g/L,
respectively.Discussion
In our pragmatic study of primarily outpatient women
attending high-risk pregnancy clinics, we found that the
random urinary PrCr was inflated when urinary creatin-
ine concentration was <3 mM, regardless of pregnancy
outcome. This relationship was indeed surprising, as
taking a ratio of protein and creatinine concentrations
should correct for urinary dilution.
Figure 3 Urinary creatinine concentration (mmol/L) according to the time of day of urine sampling (24 hour clock).
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low urinary creatinine concentrations, we considered both
physiological and analytical explanations. First, we saw
inflated random urinary PrCr results when analyses were
restricted to women with urine samples with SG >1.010 orTable 2 N (%) of samples with urinary PrCr ≥ 30 mg/mmol acc
study and two other study cohorts from the same (our) instit
Current study (N = 160 women)
All samples in current study
All samples from women with known normal pregnancy outcome
Last urine sample from all women
Last urine sample from women with known normal pregnancy outcome
Last urine sample from women with urinary SG >1.010
Last urine sample excluding samples with dipstick hematuria or leukocytes
24 hour completeness cohort [6] (N = 198 women)
Last sample per woman
PIERS study cohort [7] (N = 931 women)
Spot PrCr (all samples)
Pyrogallol red proteinuria assay
Vitros proteinuria assay
24-hour PrCr (all samples)
Pyrogallol red proteinuria assay
Vitros proteinuria assay
PrCr (protein:creatinine) ratio.those with no dipstick hematuria or leukocytes. Second,
considering that proteinuria in pregnancy is measured
primarily to detect pre-eclampsia, either de novo or
superimposed on pre-existing hypertension (present in
15% of our cohort), it must be noted that women with pre-ording to urinary creatinine concentrations, in current
ution
N urine samples Urinary creatinine concentration
N (%) samples
<3 mM ≥3 mM p value
233 64/68 (94.1%) 27/165 (16.4%) <0.001
45 13/14 (92.9%) 0/31 <0.001
160 47/50 (94.0%) 17/110 (15.4%) <0.001
32 10/11 (90.9%) 0/21 <0.001
104 9/11 (81.8%) 12/93 (12.9%) <0.001
98 37/39 (94.9%) 10/59 (16.9%) <0.001
197 12/18 (66.7%) 99/179 (55.3%) 0.354
N = 601 N = 1285
2432 482/655 (73.6%) 1089/1777 (61.3%) <0.001
468 119/122 (97.5%) 196/346 (56.6%) <0.001
N = 103 N = 331
607 92/125 (73.6%) 313/482 (64.9%) 0.067
43 11/11 (100%) 18/32 (56.3%) 0.008
Figure 4 All 24-hour PrCr results using the pyrogallol red dye from a published cohort of women with 24-hour urine collection6. The
horizontal dotted line represents a PrCr of 30 mg/mmol, the current cut-off for detection of 0.3 g/d of proteinuria. The vertical dotted line
represents a urinary creatinine concentration of 3 mmol/L.
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if anything, they should have decreased urine volumes (or
even oliguria) and elevated (not decreased) urinary creatin-
ine concentrations. Many of these women are placed on
bedrest, but this would not account for decreased urinary
creatinine concentration because the natural history of
pre-eclampsia is too short to have a significant impact on
muscle mass (and urinary creatinine excretion); women at
term gestations are delivered right away [8] and those
remote from term are delivered for maternal/fetal reasons
either right away (40%) or on average, within 10–14 days
(30%) [9]. Third, in considering the role of analyticalTable 3 Dilution studies using a standard urine specimen con









Undiluted 0.335 g/L n/a
1:2 0.168 g/L 0.242 g/L
1:3 0.112 g/L 0.199 g/L
1:4 0.084 g/L 0.183 g/L
1:5 0.067 g/L 0.172 g/L
n/a (not applicable).
* Water measured on its own yielded a protein concentration of 0.12 g/L.
† The unexpectedly high result for underlines the problem with dilute samples. The
calibrators contain protein (bovine serum albumin) added to a synthetic urine matr
containing calibrators are targeted at 0.80 and 2.10 g/L and the curve is extrapolate
Vitros methods, the lower analytical limit is defined by performance (precision and
works optimally at the ionic strength of non-dilute urine (due to the various ions pr
in a low ionic strength solution (such as pure water or saline), the dye binding char
‡ Saline on its own yielded a proteinuria concentration of 0.06 g/L.methods, in two other patient cohorts from our centre
(which used pyrogallol red dye-based protein assays until
2009, and Vitros thereafter) random urinary PrCr results
were inflated in samples tested by the Vitros compared to
those tested using pyrogallol red. Of particular note, 10%
of 24-hour urine samples were dilute [6] and thus, subject
to the same problem as the random urine samples in
the current study. Finally, dilution studies showed that
using our pyrocatechol violet molybdate dye-binding
method on the Vitros analyser, there was overestimation
of urine protein as dilution increased, and even pure
water and saline contained ‘measurable’ protein. Thistaining 0.335 g/L of protein and either deionized water
Measured proteinuria concentration




Recovery of proteinuria as a
% of expected
n/a n/a n/a
144% 0.183 g/L 109%
178% 0.140 g/L 125%
219% 0.118 g/L 141%
257% 0.106 g/L 158%
assay is optimized for measuring urine, not aqueous samples. Method
ix with inorganic salts, a polymer, preservatives and stabilizers. Protein
d down. The low end is verified with a calibrator at less than 0.15 g/L. In the
linearity studies) at a low level in urine or synthetic urine samples. The dye
esent), so that protein as low as 0.05 g/L can be detected with confidence. But
acteristics result in false detection of protein.
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results were inflated in dilute urines because of falsely
high urine protein results.
These results helped to explain both our clinical obser-
vations that some women with elevated random urinary
PrCr results had normal pregnancy outcome, as well as
the findings of a previous report of unexplained protein-
uria of 0.38 g/d associated with high water intake (and low
24-hour urinary creatinine concentration of 2.9 mM) in
63 people in a community screening study [3]. In that
published study, the Vitros 950 autoanalyser was used to
measure protein, and when 56 of the subjects agreed to
decrease their water intake, urine protein significantly de-
creased (to 0.16 g/d, associated with an increase in urinary
creatinine concentration to 6.9 mM).
The manufacturer of the Vitros urine protein assay (Or-
tho-Clinical Diagnostics, Rochester, NY) has documented
that when urinary SG is ≤1.010, measurement of 24-hour
urine protein excretion may be falsely elevated as a limita-
tion of the assay [5]. We found, however, that urine cre-
atinine <3 mM was more effective than urine SG ≤1.010
for identifying dilute samples in which random urinary
PrCr was overestimated; the inaccuracy of urine dipstick
SG compared to other measures of urine concentration is
well documented [10], whereas the use of creatinine to
correct for variability in urine concentration is the prem-
ise of PrCr assessment [1]. The overestimation is attrib-
uted to the fact that the accuracy of pyrocatechol violet
molybdate dye-binding relies on the ionic strength of the
urine. Lower ionic strength (as seen in dilute urine) may
result in more dye-binding and higher measured protein
concentrations [11]. This overestimation by Vitros of pro-
tein concentration in dilute urine has been previously
published [11,12]. Consistent with the manufacturer’s ex-
planation was our observation that when saline was used
as the diluent in our dilution studies (thus, offering some
ionic strength from the sodium chloride), inflation of urin-
ary protein measurement seen with use of deionised water
was attenuated. Although this study showed that protein-
uria results were inflated in dilute urine because of analyt-
ical bias, it is to be noted that the use of creatinine may
also fail to correct for urinary dilution in very dilute urines
for other analytes, for example, as demonstrated for urin-
ary albumin [13].
Our 2008 review of the diagnostic accuracy of the
random urinary PrCr concluded that it is a “reasonable”
rule-out test for detecting proteinuria of ≥0.3 g/d in
hypertensive pregnancy [14]. Our findings in the current
study should have no impact on this conclusion. Al-
though that review could not examine the impact of
urine protein assay method on the results because of in-
complete reporting of methods, none of the included
studies used the current Vitros method; five used the
dye pyrogallol red.It should be highlighted that this is not a problem re-
stricted to random urinary samples; 10% of 24-hour
urine collections may be dilute (i.e., have urinary creatin-
ine <3 mM) [6] and proteinuria is assayed in 24-hour
urine samples by taking a sample, measuring the urine
protein concentration, and then multiplying it by the
volume of urine submitted to get the value for protein
excretion in g/d.
The impact on maternal management of a false positive
proteinuria result may include patient anxiety and greater
use of health care resources due to enhanced maternal
and fetal surveillance (as a diagnosis of pre-eclampsia is
associated with both maternal and perinatal risk), hospital
admission, and/or earlier delivery [2]. Higher costs related
to misclassification of renal function related to creatinine
standardization have also been previously published [15].
The first strength of our study is that in our current
study cohort, we maximised generalisability by assessing a
broad spectrum of (primarily outpatient) high-risk pa-
tients with and without significant proteinuria as diag-
nosed by a random urinary PrCr of ≥30 mg/mmol. We
also expanded our analyses to two other cohorts of pri-
marily inpatient women with pre-eclampsia. Second, we
performed an additional exploratory dilution study using
the Vitros proteinuria method, and validated our result in
two separate cohorts of women with proteinuria measure-
ment by a different dye-based method (i.e., pyrogallol red).
Some would point out that the random urinary PrCr re-
sult was not compared to 24-hour urinary protein; how-
ever, it must be acknowledged that the 24-hour urine
collection is frequently incomplete in pregnancy and as
such, is no longer considered to be the gold standard for
diagnosis of proteinuria in pregnancy [6].
Conclusions
In conclusion, our Vitros random urinary PrCr results
were inflated in dilute urines because of overestimation of
urine protein as a result of technical limitations of the py-
rocatechol violet dye-based assay, as confirmed by dilution
studies. We observed this phenomenon in another cohort
in which Vitros was used. However, the effect was greatly
reduced when examining data from two other independ-
ent cohorts from our centre in which pyrogallol red was
the dye used in the urine protein assay.
Future directions
Our study highlights the need for both follow-up of
clinical observations as well as collaboration between cli-
nicians and laboratory medicine specialists. At our tertiary
perinatal unit where proteinuria assessment is done
largely to detect proteinuria in pregnancy, we will be
reassessing our assay. Pending future clarification, it may
be prudent for clinicians to focus on first voided urines
when at all possible, and when not, to consider the
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when urinary creatinine concentration is <3 mM. This
cautionary note also applies to 24-hour urine collections.
It is not known whether urinary dilution has an impact on
the accuracy of proteinuria assessment by other methods
(dye-based or other), for both random urinary PrCr test-
ing and 24-hour urinary protein determination. Given the
importance of proteinuria assessment both in and outside
pregnancy, laboratory standardization should be vigor-
ously pursued.Additional files
Additional file 1: Figure S1. Random urinary protein:creatinine ratio
(PrCr, mg/mmol) according to urinary creatinine concentration (mmol/L),
presented by type of urine protein assay. A) Pyrogallol red urine assay. B)
Vitros urine protein assay. The horizontal dotted line represents a PrCr of
30 mg/mmol, the current cut-off for detection of 0.3 g/d of proteinuria.
The vertical dotted line represents a urinary creatinine concentration of
3 mmol/L.
Additional file 2: Figure S2. Protein concentration result (g/L) using a
standard urine specimen containing 0.335 g/L of protein according to
various sample:diluent ratios of either deionized water or saline as the
diluent (Table 3).
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